GlassScriptPhysician profile
Steven B Goodman
NPI 1295775328
$4,134.64
in general payments reported to CMS, 2019-2025
28 companies · $763 in 2025
The $763 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $596 · 2020: $633 · 2021: $663 · 2022: $354 · 2023: $485 · 2024: $640 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,888.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $727.40 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $452.68 | 2019-2025 | |
| Novo Nordisk INC | $413.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $336.09 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $292.24 | 2021-2025 | |
| Lilly USA, LLC | $285.35 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $250.33 | 2019-2025 | Repatha, Krystexxa, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.48 | 2020-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $163.06 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $143.50 | 2019-2023 | Verquvo, Januvia, Belsomra |
| Allergan, INC. | $109.15 | 2019-2020 | |
| Amarin Pharma, INC. | $101.11 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $92.53 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.40 | 2020-2024 | Trintellix |
| Exact Sciences Corporation | $64.31 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $61.52 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.91 | 2024-2025 | |
| Gilead Sciences, INC. | $51.78 | 2019-2021 | |
| Biotronik Nro, INC. | $45.95 | 2025 | Prospera |
| Idorsia Pharmaceuticals US INC | $37.30 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $28.26 | 2024 | Voquezna |
| Eisai INC. | $27.50 | 2020-2021 | |
| Abbott Laboratories | $22.46 | 2025 | Eterna |
| Sumitomo Pharma America, INC. | $21.24 | 2025 | Gemtesa |
| Corcept Therapeutics | $20.05 | 2025 | Korlym |
| Jazz Pharmaceuticals INC. | $19.07 | 2020 | |
| Astellas Pharma US INC | $17.90 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.